Vitamin D and Omega-3 Hypertension Trial (VITAL Hypertension)

This study is enrolling participants by invitation only.
Sponsor:
Collaborator:
Information provided by (Responsible Party):
Howard D. Sesso, ScD, MPH, Brigham and Women's Hospital
ClinicalTrials.gov Identifier:
NCT01653678
First received: July 27, 2012
Last updated: October 16, 2012
Last verified: October 2012
  Purpose

The VITamin D and OmegA-3 TriaL (VITAL; NCT 01169259) is a randomized clinical trial in 20,000 U.S. men and women investigating whether taking daily dietary supplements of vitamin D3 (2000 IU) or omega-3 fatty acids (Omacor® fish oil, 1 gram) reduces the risk of developing cancer, heart disease, and stroke in people who do not have a prior history of these illnesses. The VITAL Hypertension ancillary study is being conducted among participants in VITAL and will examine whether vitamin D or omega-3 fatty acids are related to changes in blood pressure and hypertension.


Condition Intervention
Hypertension
Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU
Drug: Omega-3 fatty acids (fish oil)
Dietary Supplement: Vitamin D placebo
Drug: Fish oil placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Efficacy Study
Intervention Model: Factorial Assignment
Masking: Double Blind (Subject, Investigator, Outcomes Assessor)
Primary Purpose: Prevention
Official Title: Effect of Vitamin D and Omega-3 Fatty Acids on Blood Pressure and Hypertension

Resource links provided by NLM:


Further study details as provided by Brigham and Women's Hospital:

Primary Outcome Measures:
  • Change in blood pressure [ Time Frame: Two years ] [ Designated as safety issue: No ]
    Change in 24-hour ambulatory blood pressure measurements among a subcohort of approximately 1,000 participants.

  • Incident hypertension [ Time Frame: 5 years ] [ Designated as safety issue: No ]
    Incidence of hypertension in the overall VITAL trial cohort.

  • Changes in 25-hydroxy-vitamin D levels [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Changes in a subcohort of approximately 1,000 participants.

  • Changes in fatty acid levels [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Changes in a subcohort of approximately 1,000 participants

  • Changes in biomarkers related to blood pressure [ Time Frame: 2 years ] [ Designated as safety issue: No ]
    Changes in a subcohort of approximately 1,000 participants


Estimated Enrollment: 20000
Study Start Date: November 2011
Estimated Study Completion Date: June 2016
Estimated Primary Completion Date: June 2016 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: Vitamin D + fish oil Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU
Other Name: cholecalciferol
Drug: Omega-3 fatty acids (fish oil)
Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
Active Comparator: Vitamin D + fish oil placebo Dietary Supplement: Vitamin D-3 (cholecalciferol), 2000 IU
Other Name: cholecalciferol
Drug: Fish oil placebo
Active Comparator: Vitamin D placebo + fish oil Drug: Omega-3 fatty acids (fish oil)
Omacor, 1 capsule per day. Each capsule of Omacor contains 840 milligrams of marine omega-3 fatty acids (465 mg of eicosapentaenoic acid [EPA] and 375 mg of docosahexaenoic acid [DHA])
Dietary Supplement: Vitamin D placebo
Placebo Comparator: Vitamin D placebo + fish oil placebo Dietary Supplement: Vitamin D placebo Drug: Fish oil placebo

Detailed Description:

The human toll of hypertension is staggering, and effective preventive measures are needed. Studies suggest that inadequate vitamin D and omega-3 fatty acid levels may be involved in the development of hypertension through multiple pathways. Results from several small clinical trials suggest that these agents may have blood pressure lowering effects, however, larger trials using higher doses of both vitamin D and omega-3 fatty acids for the prevention of hypertension among people with normal blood pressure levels are lacking. The VITamin D and OmegA-3 TriaL (VITAL) provides a cost-effective setting to examine the effects of both study agents on changes in blood pressure and new diagnoses of hypertension.

VITAL Hypertension will test the following hypotheses: (1) whether vitamin D and fish oil supplementation lowers 24-hour blood ambulatory blood pressure (ABP) compared to placebo in a subcohort of 1,000 participants; (2) whether vitamin D and fish oil supplementation reduces the risk of incident hypertension compared to placebo among all randomized VITAL participants without baseline hypertension; and (3) whether vitamin D and fish oil supplementation favorably change hypertension-related biomarkers that are potential mechanisms linking vitamin D and omega-3 fatty acids with hypertension compared to placebo.

A representative subcohort of 1,000 VITAL participants without hypertension from selected major metropolitan areas throughout the US will be invited to participate in home-based study visits at baseline and 2 years follow-up. During these visits, participants will be asked to wear monitors to record 24-hour ABP measurements, provide fasting bloods, spot urine samples, and other clinical measurements. The visits will be conducted by Examination Management Services, Inc. (EMSI), a nationally based, clinical services provider. We will compare 2-year changes in ABP among those randomized to vitamin D and omega-3 fatty acid supplements versus those randomized to placebo. In addition, we will assess the 2-year changes in levels of clinically and mechanistically relevant biomarkers of hypertension compared the 2 treatment groups.

New diagnoses of hypertension among all VITAL participants will be ascertained on annual follow-up questionnaires. To strengthen our classification of hypertension status, we will supplement our questionnaire data with annual updates of hypertension information based upon outpatient diagnostic codes and medication prescription usage from the Centers for Medicare & Medicaid Services (CMS) database. Incidence of hypertension among those assigned to each active agent versus placebo will be compared.

In addition, baseline blood samples from 1,000 participants with new diagnoses of hypertension will be compared with those from 2,000 participants without hypertension to determine whether the effect of vitamin D and/or omega-3 fatty acid supplements on the incidence of hypertension is modified by baseline plasma levels of vitamin D or omega-3 fatty acids.

Results from VITAL Hypertension will provide important evidence to support or refute the potential preventive roles of vitamin D and omega-3 fatty acids on blood pressure and the development of hypertension.

  Eligibility

Ages Eligible for Study:   50 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Participants eligible and willing to participate in the main VITAL trial (NCT 01169259) who meet the following criteria are eligible to participate in the VITAL Hypertension ancillary study: all participants with no baseline history of hypertension and, for home visits in the subcohort of 1,000 participants, those living in selected cities throughout the U.S..

  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT01653678

Locations
United States, Massachusetts
Brigham and Women's Hospital
Boston, Massachusetts, United States, 02215
Sponsors and Collaborators
Brigham and Women's Hospital
Investigators
Principal Investigator: Howard D. Sesso, ScD, MPH Brigham and Women's Hospital
Principal Investigator: John P. Forman, MD Brigham and Women's Hospital
  More Information

Additional Information:
No publications provided

Responsible Party: Howard D. Sesso, ScD, MPH, Principal Investigator, Brigham and Women's Hospital
ClinicalTrials.gov Identifier: NCT01653678     History of Changes
Other Study ID Numbers: 2010-P-002880, 1R01HL102122
Study First Received: July 27, 2012
Last Updated: October 16, 2012
Health Authority: United States: Food and Drug Administration

Keywords provided by Brigham and Women's Hospital:
vitamin D-3
omega-3 fatty acids
fish oil
hypertension
blood pressure

Additional relevant MeSH terms:
Hypertension
Vascular Diseases
Cardiovascular Diseases
Cholecalciferol
Vitamin D
Ergocalciferols
Vitamins
Micronutrients
Growth Substances
Physiological Effects of Drugs
Pharmacologic Actions
Bone Density Conservation Agents

ClinicalTrials.gov processed this record on April 17, 2014